Global Pseudobulbar Affect Treatment Market Report and Forecast 2024-2032

Global Pseudobulbar Affect Treatment Market Outlook

The global pseudobulbar affect treatment market is expected to grow at a CAGR of 9.20% during the forecast period of 2024-2032, driven by the rising prevalence of neurological disorders.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Pseudobulbar Affect Treatment Market Trends

Pseudobulbar affect is a neurological disorder that causes sudden outbursts of laughter or crying that are uncontrollable. This condition can either develop through a brain injury or an underlying neurological condition, such as amyotrophic lateral sclerosis. Although there is no guaranteed cure available for the condition, there are medications available that can help in managing it.

• The rising prevalence of the pseudobulbar affect is expected to enhance the market size as it has propelled the demand for effective treatment solutions that can help with the symptoms of the disorder. Healthcare providers and centres are increasingly providing advanced and improved treatment methods to patients to meet the rising demand.

• The market for pseudobulbar affect treatment is expected to develop significantly owing to the increasing investments in healthcare infrastructure development. Multiple government organisations have increased their healthcare expenditure to improve the infrastructure and facilities.

• The rising number of initiatives taken by various organisations to develop innovative and improved treatment options can further propel awareness about treatment solutions. In addition, it will further enhance the demand for treatments in the market, which will augment the market value.

Global Pseudobulbar Affect Treatment Market Analysis

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on treatment, the market can be segmented into medication and occupational therapy, among others. Based on the route of administration, it can be bifurcated into oral and parental, among others. Based on drug class, the market divisions include antidepressants and nuedexta, among others. Based on distribution channels, the market can be segmented into retail pharmacies, hospital pharmacies, and online, among others. The regional markets for the pseudobulbar affect treatment market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. 

The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global pseudobulbar effect treatment market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments and expansion plans.

• Avanir Pharmaceuticals, Inc.

• Pfizer Inc.

• Eli Lilly and Company

• Arrow Pharmaceuticals

• AbbVie Inc.

• Others

Treatment Types for Pseudobulbar Affect Treatment in the Market

The market for pseudobulbar affect treatment, based on product type, can be bifurcated into medication and occupational therapy, among others.

The medication segment is expected to hold a major share of the market owing to rising efforts and investments to develop new and improved medications. Although companies are trying to develop new treatment options, there is only one medication approved by the Food and Drug Administration known as Dextromethorphan hydrobromide and quinidine sulfate (Nuedexta), which is specifically developed for Pseudobulbar affect treatment (PBA).

Regional Outlook for the Pseudobulbar Affect Treatment Global Market

Based on regional markets, the market divisions include North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.

North America is expected to dominate the pseudobulbar affect treatment market due to the rising prevalence of neurological disorders. The market development is aided by the growing geriatric population in the region. Furthermore, growing healthcare expenditures and the presence of significant key competitors will drive the market's growth rate in this region even faster.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

Avanir Pharmaceuticals, Inc., was founded in 1988 and the headquarter is located in California, United States. It is a pharmaceutical manufacturing company that operates in the field with an aim to deliver innovative medicines to patients with central nervous system disorders. The company is a subsidiary of Otsuka America, Inc. (OAI), which is a holding company established in the United States in 1989.

Pfizer Inc. is a pharmaceutical and biotechnology company, headquartered in New York City, United States. The company was established in 1849 and they were one of the leading figures engaged in the development of a vaccine for COVID-19. Since the beginning of its operations, the company has evolved their product portfolio to include multitudes of products like Comirnaty, Eliquis, Ibrance, Prevnar family, and Xeljanz. 

Eli Lilly and Company. is a global pharmaceutical company, which was founded in 1876 and headquartered in Indianapolis, United States. The company’s speciality lies in pharmaceutical development, biotech, and biopharmaceuticals. They have expertise in disease areas, such as Alzheimer’s, cancer, diabetes, immunology, obesity, and pain.

Other market players include Arrow Pharmaceuticals and AbbVie Inc., among others.

Key Highlights of the Report